Comparative Pharmacology
Head-to-head clinical analysis: FORTAMET versus LYUMJEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAMET versus LYUMJEV.
FORTAMET vs LYUMJEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
LYUMJEV (insulin lispro-aabc) is a rapid-acting insulin analog that binds to the insulin receptor (IR), activating the IR tyrosine kinase cascade. This leads to increased glucose uptake in peripheral tissues (primarily skeletal muscle and adipose tissue), inhibition of hepatic gluconeogenesis, and promotion of glycogen synthesis. The aabc amino acid substitution (insulin lispro with proline at B28 replaced by lysine and lysine at B29 replaced by proline, plus an additional modification) results in faster dissociation from the insulin receptor and accelerated absorption from subcutaneous tissue compared to regular human insulin.
Initial: 500 mg orally twice daily or 1000 mg orally once daily; titrate in increments of 500 mg weekly; maximum daily dose: 2000 mg.
Subcutaneous injection at mealtime (within 15 minutes before or immediately after meal). Doses individualized; typical range 0.2-1.0 units/kg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6.2 hours (range 4–9 hours) in patients with normal renal function; half-life is prolonged in renal impairment (up to 18 hours in moderate impairment and 24 hours in severe impairment).
Terminal elimination half-life of LYUMJEV (insulin lispro) is approximately 13.7 minutes (0.23 hours) in healthy subjects, reflecting rapid clearance from the bloodstream.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; the remainder is excreted fecally (via bile).
Primarily renal; approximately 90% of absorbed dose is excreted via urine as metabolites and unchanged drug, with the remainder eliminated in feces (<10%).
Category C
Category C
Antidiabetic
Antidiabetic